Literature DB >> 25003953

Reciprocal regulation of human platelet function by endogenous prostanoids and through multiple prostanoid receptors.

Katharina Hubertus1, Marcel Mischnik2, Jens Timmer3, Sabine Herterich1, Regina Mark1, Maxime Moulard4, Ulrich Walter5, Joerg Geiger6.   

Abstract

Platelets are permanently exposed to a variety of prostanoids formed by blood cells or the vessel wall. The two major prostanoids, prostacyclin and thromboxane act through well established pathways mediated by their respective G-protein coupled receptors inhibiting or promoting platelet aggregation accordingly. Yet the role of other prostanoids and prostanoid receptors for platelet function regulation has not been thoroughly investigated. We aimed at a comprehensive analysis of prostanoid effects on platelets, the receptors and pathways involved and functional consequences. We analyzed cAMP formation and phosphorylation of proteins pivotal to platelet function as well as functional platelet responses such as secretion, aggregation and phosphorylation. The types of prostanoid receptors contributing and their individual share in signaling pathways were analyzed and indicated a major role for prostanoid IP1 and DP1 receptors followed by prostanoid EP4 and EP3 receptors while prostanoid EP2 receptors appear less relevant. We could show for the first time the reciprocal action of the endogenous prostaglandin PGE2 on platelets by functional responses and phosphorylation events. PGE2 evokes stimulatory as well as inhibitory effects in a concentration dependent manner in platelets via prostanoid EP3 or EP4 and prostanoid DP1 receptors. A mathematical model integrating the pathway components was established which successfully reproduces the observed platelet responses. Additionally we could show that human platelets themselves produce sufficient PGE2 to act in an autocrine or paracrine fashion. These mechanisms may provide a fine tuning of platelet responses in the circulating blood by either promoting or limiting endogenous platelet activation.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  BW245c (CID 119304); BW868C (CID 57340013); CAY 10441 (CID 9839644); Cyclic AMP; L161,982 (CID 9961192); L798,106 (CID 15551229); P2Y12; Prostaglandin A1; Prostaglandin E2-synthase; Secretion; U46619 (CID 5311493); VASP; butaprost (CID 5311035); cangrelor (CID 9854012); iloprost (CID 5311181); prostaglandin A(1) (CID 5281912); prostaglandin D(2) (CID 448457); prostaglandin E(1) (CID 5280723); prostaglandin E(2) (CID 5280360); sulprostone (CID 5312153)

Mesh:

Substances:

Year:  2014        PMID: 25003953     DOI: 10.1016/j.ejphar.2014.06.030

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

1.  12-HETrE inhibits platelet reactivity and thrombosis in part through the prostacyclin receptor.

Authors:  Benjamin E Tourdot; Reheman Adili; Zitha R Isingizwe; Meral Ebrahem; J Cody Freedman; Theodore R Holman; Michael Holinstat
Journal:  Blood Adv       Date:  2017-06-23

2.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

3.  Activated Platelets Induce an Anti-Inflammatory Response of Monocytes/Macrophages through Cross-Regulation of PGE2 and Cytokines.

Authors:  Bona Linke; Yannick Schreiber; Bettina Picard-Willems; Patrick Slattery; Rolf M Nüsing; Sebastian Harder; Gerd Geisslinger; Klaus Scholich
Journal:  Mediators Inflamm       Date:  2017-05-16       Impact factor: 4.711

Review 4.  Effect of Prostanoids on Human Platelet Function: An Overview.

Authors:  Steffen Braune; Jan-Heiner Küpper; Friedrich Jung
Journal:  Int J Mol Sci       Date:  2020-11-27       Impact factor: 5.923

5.  ML355 Modulates Platelet Activation and Prevents ABT-737 Induced Apoptosis in Platelets.

Authors:  Valentina Shpakova; Natalia Rukoyatkina; Nada Al Arawe; Anna Prilepskaya; Alexandra Kharazova; Iraida Sharina; Stepan Gambaryan; Emil Martin
Journal:  J Pharmacol Exp Ther       Date:  2022-02-23       Impact factor: 4.402

Review 6.  The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD.

Authors:  Martin Kolb; Stylianos E Orfanos; Chris Lambers; Kevin Flaherty; Alison Masters; Lisa Lancaster; Adam Silverstein; Steven D Nathan
Journal:  Adv Ther       Date:  2022-07-03       Impact factor: 4.070

7.  Treprostinil inhibits proliferation and extracellular matrix deposition by fibroblasts through cAMP activation.

Authors:  Christopher Lambers; Michael Roth; Peter Jaksch; Gabriella Muraközy; Michael Tamm; Walter Klepetko; Bahil Ghanim; Feng Zhao
Journal:  Sci Rep       Date:  2018-01-18       Impact factor: 4.379

Review 8.  Prostaglandins in the pathogenesis of kidney diseases.

Authors:  Yuanyuan Li; Weiwei Xia; Fei Zhao; Zhaoying Wen; Aihua Zhang; Songming Huang; Zhanjun Jia; Yue Zhang
Journal:  Oncotarget       Date:  2018-05-29

Review 9.  Cyclic nucleotide-dependent inhibitory signaling interweaves with activating pathways to determine platelet responses.

Authors:  Zoltan Nagy; Albert Smolenski
Journal:  Res Pract Thromb Haemost       Date:  2018-06-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.